387 related articles for article (PubMed ID: 34422657)
1. Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications.
Comba A; Faisal SM; Varela ML; Hollon T; Al-Holou WN; Umemura Y; Nunez FJ; Motsch S; Castro MG; Lowenstein PR
Front Oncol; 2021; 11():703764. PubMed ID: 34422657
[TBL] [Abstract][Full Text] [Related]
2. Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains.
Moffet JJD; Fatunla OE; Freytag L; Kriel J; Jones JJ; Roberts-Thomson SJ; Pavenko A; Scoville DK; Zhang L; Liang Y; Morokoff AP; Whittle JR; Freytag S; Best SA
Neurooncol Adv; 2023; 5(1):vdad142. PubMed ID: 38077210
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
5. Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion.
Comba A; Dunn PJ; Kish PE; Kadiyala P; Kahana A; Castro MG; Lowenstein PR
J Vis Exp; 2020 Apr; (158):. PubMed ID: 32338655
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
7. Developmental origins and oncogenic pathways in malignant brain tumors.
Lu QR; Qian L; Zhou X
Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
[TBL] [Abstract][Full Text] [Related]
8. Role and mechanism of neural stem cells of the subventricular zone in glioblastoma.
Zhang GL; Wang CF; Qian C; Ji YX; Wang YZ
World J Stem Cells; 2021 Jul; 13(7):877-893. PubMed ID: 34367482
[TBL] [Abstract][Full Text] [Related]
9. Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology.
Becker AP; Sells BE; Haque SJ; Chakravarti A
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673104
[TBL] [Abstract][Full Text] [Related]
10. The landscape of the mesenchymal signature in brain tumours.
Behnan J; Finocchiaro G; Hanna G
Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
[TBL] [Abstract][Full Text] [Related]
11. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
13. A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors.
Costa B; Fletcher MNC; Boskovic P; Ivanova EL; Eisemann T; Lohr S; Bunse L; Löwer M; Burchard S; Korshunov A; Coltella N; Cusimano M; Naldini L; Liu HK; Platten M; Radlwimmer B; Angel P; Peterziel H
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435218
[TBL] [Abstract][Full Text] [Related]
14. Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression.
Comba A; Faisal SM; Dunn PJ; Argento AE; Hollon TC; Al-Holou WN; Varela ML; Zamler DB; Quass GL; Apostolides PF; Abel C; Brown CE; Kish PE; Kahana A; Kleer CG; Motsch S; Castro MG; Lowenstein PR
Nat Commun; 2022 Jun; 13(1):3606. PubMed ID: 35750880
[TBL] [Abstract][Full Text] [Related]
15. Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas.
Kiesel B; Mischkulnig M; Woehrer A; Martinez-Moreno M; Millesi M; Mallouhi A; Czech T; Preusser M; Hainfellner JA; Wolfsberger S; Knosp E; Widhalm G
J Neurosurg; 2018 Aug; 129(2):341-353. PubMed ID: 29076783
[TBL] [Abstract][Full Text] [Related]
16. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
17. Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.
Onciul R; Brehar FM; Toader C; Covache-Busuioc RA; Glavan LA; Bratu BG; Costin HP; Dumitrascu DI; Serban M; Ciurea AV
Curr Issues Mol Biol; 2024 Mar; 46(3):2402-2443. PubMed ID: 38534769
[TBL] [Abstract][Full Text] [Related]
18. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions.
Gagliardi F; Narayanan A; Reni M; Franzin A; Mazza E; Boari N; Bailo M; Zordan P; Mortini P
Glia; 2014 Jul; 62(7):1015-23. PubMed ID: 24715652
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic Transition as a Survival Strategy of Glioma.
Ichikawa T; Otani Y; Kurozumi K; Date I
Neurol Med Chir (Tokyo); 2016 Jul; 56(7):387-95. PubMed ID: 27169497
[TBL] [Abstract][Full Text] [Related]
20. DHHC protein family targets different subsets of glioma stem cells in specific niches.
Chen X; Hu L; Yang H; Ma H; Ye K; Zhao C; Zhao Z; Dai H; Wang H; Fang Z
J Exp Clin Cancer Res; 2019 Jan; 38(1):25. PubMed ID: 30658672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
